Safety Profile
Known Safety Concerns
- No established human biological requirement
- Mimics potassium -- cardiac and neuromuscular effects
- CNS excitation at higher doses
- No safe supplemental dose established
Contraindications
- No established human biological requirement
- Mimics potassium -- cardiac and neuromuscular effects
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Rubidium is a trace alkali metal with no established essential function in human nutrition. Mimics potassium in biological systems. At pharmacological doses causes CNS excitation, hypertension, and potentially cardiac arrhythmia. No legitimate supplement use is supported by evidence.
Biological and Chemical Classification
- Scientific Name
- Rubidium (various salts)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Mineral
- Evidence consistency: High consistency across studies (100%)
- No established human biological requirement
- Mimics potassium -- cardiac and neuromuscular effects
- CNS excitation at higher doses
- No safe supplemental dose established
The available scientific evidence for Rubidium indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 22:48
Evidence Distribution
-
Observational / other LOW evidence YELLOWQuantifying what matters: Clarifying the value of longitudinal flow gradients in [82Rb]rubidium-positron emission tomography myocardial perfusion imaging. ↗Murphy NP et al.. Quantifying what matters: Clarifying the value of longitudinal flow gradients in [82Rb]rubidium-positron emission tomography myocardial perfusion imaging.. J Nucl Cardiol. 2026. PMID:41866687.PMID 41866687 ↗Journal J Nucl CardiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41866687/
-
Observational / other LOW evidence YELLOWLow-SWaP, tunable, and narrow-linewidth laser systems for deployable quantum technologies. ↗Corato-Zanarella M et al.. Low-SWaP, tunable, and narrow-linewidth laser systems for deployable quantum technologies.. Opt Express. 2026. PMID:41845855.PMID 41845855 ↗Journal Opt ExpressYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41845855/
-
Observational / other LOW evidence YELLOWSaturated absorption spectroscopy for spatially resolved flow velocimetry. ↗Roy S et al.. Saturated absorption spectroscopy for spatially resolved flow velocimetry.. Appl Opt. 2026. PMID:41842408.PMID 41842408 ↗Journal Appl OptYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41842408/
-
Observational / other LOW evidence YELLOWEfficient and robust spatial-to-fiber coupling-with scalability to multimode quantum networks via the cascaded adaptive feedback control system. ↗Li Y et al.. Efficient and robust spatial-to-fiber coupling-with scalability to multimode quantum networks via the cascaded adaptive feedback control system.. Appl Opt. 2026. PMID:41841848.PMID 41841848 ↗Journal Appl OptYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41841848/
-
Observational / other LOW evidence YELLOWResolution of Microvascular Ischemia Following Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: Evidence from Rubidium-82 PET. ↗Melhem HB et al.. Resolution of Microvascular Ischemia Following Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: Evidence from Rubidium-82 PET.. J Nucl Cardiol. 2026. PMID:41831813.PMID 41831813 ↗Journal J Nucl CardiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41831813/
-
Observational / other LOW evidence YELLOWA Single-Cell Optically Pumped Intrinsic Gradiometer. ↗Zilinski N et al.. A Single-Cell Optically Pumped Intrinsic Gradiometer.. Sensors (Basel). 2026. PMID:41829639.PMID 41829639 ↗Journal Sensors (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41829639/
-
Observational / other LOW evidence YELLOWPotassium Hexafluoroacetylacetonate Complex with 18-Crown-6 Ether as a Volatile Precursor of Molecular and Inorganic Films: Thermal and Structural Insights. ↗Kochelakov DV et al.. Potassium Hexafluoroacetylacetonate Complex with 18-Crown-6 Ether as a Volatile Precursor of Molecular and Inorganic Films: Thermal and Structural Insights.. Int J Mol Sci. 2026. PMID:41828376.PMID 41828376 ↗Journal Int J Mol SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41828376/
-
Observational / other LOW evidence YELLOWComparative study of Raman-coherence-assisted nonlinear magneto-optical rotation in D1 and D2 transitions using cold rubidium atoms. ↗Yin Y et al.. Comparative study of Raman-coherence-assisted nonlinear magneto-optical rotation in D1 and D2 transitions using cold rubidium atoms.. Opt Lett. 2026. PMID:41824695.PMID 41824695 ↗Journal Opt LettYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41824695/
-
Observational / other LOW evidence YELLOWCarrier Regulation and Interface Catalysis Synergy Enhance the Water Splitting Efficiency of Perovskite Photoelectrodes. ↗Li Y et al.. Carrier Regulation and Interface Catalysis Synergy Enhance the Water Splitting Efficiency of Perovskite Photoelectrodes.. ACS Appl Mater Interfaces. 2026. PMID:41818603.PMID 41818603 ↗Journal ACS Appl Mater InterfacesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41818603/
-
Observational / other LOW evidence YELLOWCalibrations of flat alkali acid phthalate crystals between 650 and 2400u2009u2009eV using synchrotron radiation. ↗Wu M et al.. Calibrations of flat alkali acid phthalate crystals between 650 and 2400u2009u2009eV using synchrotron radiation.. Appl Opt. 2025. PMID:41842518.PMID 41842518 ↗Journal Appl OptYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41842518/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Rubidium. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Rubidium
A score of 5.0 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.